Skip to main content
DLHC $4.66 -1.58%
DLHC logo

DLHC · DLH Holdings Corp.

Track DLHC — free
$4.66 -0.08 (-1.58%) At close · Aug 14
Market Cap
$67.54M
Shares
14.49M
All earnings calls

Earnings call · FY2026 Q1

DLH Holdings Corp. Q1 FY2026 Earnings Call

DLH Holdings Corp. Q1 FY2026 Earnings Call

Concluded Feb 10, 2026
Feb 10, 2026 31 turns
Period
FY2026 Q1
Runtime
Sources
3 artifacts

Executive readout · one minute

What matters this quarter

DLH reported Q1 FY2026 revenue of $68.9M, down 24.1% year-over-year largely due to small-business set-aside transitions (~$18M impact from CMOP and Head Start), while adjusted EBITDA margin improved sequentially to 9.5% and management expects stronger performance exiting FY2026.

Commercial and biotech opportunity exploration 25 Revenue decline from program transitions 22 Deleveraging and balance sheet 12 Budget clarity and federal funding outlook 6 Federal health modernization and cybersecurity 6 Margin improvement and cost discipline 6

Management tone

Positive

Net tone +22 · moderate hedging

Grounding quotes
  • “While revenue was down year-over-year, largely due to our previously discussed program transitions to small business set-aside contracts, such as the CMOP and Head Start. We are seeing improved visibility and are encouraged by the midterm outlook.”
  • “We expect that to have a positive impact. Notably, key federal health agencies received funding increases compared to the fiscal 2025 levels, reversing in part previously disclosed funding reductions to our current and addressable markets.”
  • “we remain on track with our debt reduction plans for fiscal 2026. Overall, we remain well positioned to succeed over the coming years, including competing effectively for high organic value opportunities within a healthy and expansive addressable market.”
  • “We have and we believe that the administration is removing some of those barriers on allowing companies and customers that have interest and capabilities to be able to move at speed consistent with commercial companies.”

Research coverage

3 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $68.89M -24.1% YoY
Diluted EPS -$0.09 -212.5% YoY
Net income -$1.32M -218.7% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Adjusted EBITDA margin improved sequentially to 9.5% in Q1 from cost-scaling actions
  • Free cash flow usage of $4.8M improved nearly $7M year-over-year from $12.1M usage
  • Recently enacted federal budget increased funding to key health agencies, partially reversing prior reductions and supporting organic growth
  • Backlog of $517.4M grew 0.6% sequentially from $514.3M
  • Management expects to convert 50%–55% of FY2026 EBITDA to debt reduction by year-end
  • Exploring targeted biotech/biopharma commercial opportunities leveraging FDA-credentialed new hire

Risks & pressure points

  • Revenue fell 24.1% YoY to $68.9M from $90.8M, driven by ~$18M CMOP/Head Start small-business set-aside transition
  • Adjusted EBITDA declined 34.3% to $6.5M from $9.9M
  • Net loss of $1.3M versus net income of $1.1M prior year; diluted EPS swung to $(0.09) from $0.08
  • Income from operations dropped 75.0% to $1.4M from $5.6M
  • Debt rose to $136.6M from $131.6M sequentially due to seasonal working capital and government shutdown impact
  • Q1 operating cash usage of $4.8M reflects seasonal working capital headwinds and timing of holiday payroll taxes

Key moments

Jump directly to management's words in the synchronized transcript.

“The management team and I are confident that DLH is on track to exit fiscal 2026 in a much stronger position than we began, and we are encouraged by what lies ahead.” Zachary C. Parker, CEO
“We remain well ahead of our mandatory term repayment schedule and in full compliance with all financial covenants. Looking ahead, we expect to convert approximately 50% to 55% of EBITDA generated during fiscal 2026 to reduce debt by year-end.” Kathryn JohnBull, CFO
Full-screen source Call document